Agios Pharmaceuticals (NASDAQ:AGIO) Earns “Outperform” Rating from Royal Bank of Canada

Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank of Canada in a research note issued to investors on Thursday, Benzinga reports. They presently have a $55.00 price target on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 20.77% from the stock’s current price.

A number of other analysts have also recently issued reports on AGIO. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. Finally, The Goldman Sachs Group raised their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $51.33.

Agios Pharmaceuticals Trading Down 0.3 %

Shares of AGIO stock opened at $45.54 on Thursday. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $50.35. The firm’s fifty day simple moving average is $45.59 and its 200 day simple moving average is $38.93. The firm has a market capitalization of $2.59 billion, a P/E ratio of -7.21 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. During the same period in the prior year, the company posted ($1.51) EPS. The firm’s quarterly revenue was up 28.4% on a year-over-year basis. Equities research analysts anticipate that Agios Pharmaceuticals will post -4.85 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is currently owned by insiders.

Institutional Trading of Agios Pharmaceuticals

Large investors have recently made changes to their positions in the business. Caxton Associates LP raised its holdings in shares of Agios Pharmaceuticals by 0.7% in the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after buying an additional 264 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 0.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 314 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its stake in shares of Agios Pharmaceuticals by 1.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock worth $911,000 after acquiring an additional 540 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals during the second quarter worth approximately $37,000. Finally, Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter valued at approximately $40,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.